Price T Rowe Associates Inc Entrada Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,049,572 shares of TRDA stock, worth $53 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,049,572
Previous 3,134,458
2.71%
Holding current value
$53 Million
Previous $44.7 Million
9.1%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding TRDA
# of Institutions
101Shares Held
28.1MCall Options Held
34.5KPut Options Held
16.4K-
Baker Bros. Advisors LP New York, NY4.87MShares$84.5 Million0.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$76.9 Million48.7% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$76.6 Million28.09% of portfolio
-
Janus Henderson Group PLC London, X01.71MShares$29.7 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$29.4 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $545M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...